CD247 and melanoma: First, Schmidt and coworkers carried out experiments in a preclinical melanoma xenograft model, reporting a marked inhibition of growth and relapse of highly tumorigenic melanoma cells through the targeting of CD20+ tumor cells with autologous T cells genetically engineered to express a chimeric CD3ζ/CD20 antigen receptor [208].